ArticleExperimental & molecular medicine2026
Iron overload reprogramming lipid metabolism through the IRP1-SCAP axis in fibroblast-like synoviocytes aggravates bone destruction in rheumatoid arthritis.
Article in Experimental & molecular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Fatty Acid Metabolic Reprogramming in Rheumatoid Arthritis: Integrating Inflammation, Resolution Failure, and Joint Destruction.Journal of inflammation research · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Rheumatoid arthritis (RA) is a leading cause of disability globally. Although iron accumulation in arthritic lesions has been observed in patients with RA, its specific contribution to disability outcomes remains unclear. Here we demonstrate a comprehensive multiomics approach to elucidate the impact and underlying mechanisms of iron overload in RA. First, clinical radiology in an RA cohort reveals a positive correlation between elevated ferrous iron levels in synovial fluid and joint damage extent. Iron chelator DFO administration significantly alleviates bone destruction in the K/BxN serum-transfer induced arthritis mice model. In terms of cellular function, we identify the aggressive migration and invasion of fibroblast-like synoviocytes (FLSs) induced by excess iron utilizing a humanized synovitis model. Mechanistically, the multiomics integration of transcriptomics and metabolomics indicates the enriched lipid synthesis pathway in the FLS response to iron exposure. The lipid transcription factor SREBP1 is particularly highly expressed in RA-FLSs, and its genetic ablation or pharmacological inhibition markedly mitigates the pathogenic effects of iron overload both in vitro and in vivo. At the molecular level, iron regulatory protein IRP1 enhances the translation of SREBP1 adapter protein SCAP by disengaging from its mRNA 5' untranslated region upon iron stimulation. This process facilitates SREBP1 cleavage and activation, driving the upregulation of genes involved in fatty acid and cholesterol biosynthesis. Our findings elucidate the IRP1-SCAP axis as a critical modulator of lipid metabolic reprogramming in aggressive FLSs, underscoring its potential as a therapeutic target for RA by modulating the 'iron-lipid' crosstalk.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.